Publications
171
Citations
1,722
Est. group size
~26
Recurring co-author estimate
Active years
15
Publishing since 2012
Samilia Obeng-Gyasi studies breast and colorectal cancer, with particular attention to how social and biological factors—such as social vulnerability, financial distress, and allostatic load (a measure of cumulative stress on the body)—affect treatment outcomes and survival. Much of this work focuses on surgical and treatment decision-making, including neoadjuvant (pre-surgery) therapy, chemotherapy use, and disparities in cancer care. This research area would suit students interested in cancer health disparities, surgical oncology outcomes, and the biological pathways linking social determinants of health to cancer prognosis.
Publication output grew substantially from 2017 to a peak in 2021, and has remained high with some fluctuation through 2025, indicating a strong and active recent research pace.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Screening and Referral for Health-Related Social Needs and Financial Distress: Current Processes Among National Cancer Institute Community Oncology Research Program Practices
JCO Oncology Practice · 2025
- An Overview of the Importance of Neoadjuvant Systemic Therapy for Breast Cancer Patients: From the Society of Surgical Oncology and the American Society of Breast Surgeons
Annals of Surgical Oncology · 2025
- The Hidden Burden: Impact of Allostatic Load on Colorectal Cancer Surgery Outcomes
Annals of Surgical Oncology · 2025
- Impact of Social Vulnerability and Allostatic Load on Postoperative Outcomes
Annals of Surgical Oncology · 2025
- Identifying and mitigating the biological effectors of the social determinants of health in cancer
JNCI Journal of the National Cancer Institute · 2025
- The Role of Allostatic Load in Breast Cancer Outcomes—Bridging Environment and Biology
JAMA Network Open · 2025
- Adjuvant Chemotherapy in Lymph Node‐Negative, <scp>T1</scp> Triple‐Negative Breast Cancer
Cancer Medicine · 2025
- Trimodal therapy is associated with higher overall survival than chemotherapy only in patients with metastatic inflammatory breast cancer
Breast Cancer Research and Treatment · 2025
- Data from Treatment and Survival Differences between Patients with Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma of the Breast
2025
- Supplementary Table S4 from Treatment and Survival Differences between Patients with Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma of the Breast
2025
- Supplementary Table S2 from Treatment and Survival Differences between Patients with Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma of the Breast
2025
- Supplementary Table S3 from Treatment and Survival Differences between Patients with Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma of the Breast
2025
- Supplementary Figure S1 from Treatment and Survival Differences between Patients with Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma of the Breast
2025
- Supplementary Figure S4 from Treatment and Survival Differences between Patients with Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma of the Breast
2025
- Supplementary Table S1 from Treatment and Survival Differences between Patients with Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma of the Breast
2025
- Annals of Surgical Oncology×34
- Journal of Clinical Oncology×9
- Surgery×7
- Journal of the American College of Surgeons×6
- JAMA Network Open×5
- Oindrila Bhattacharyya
Medicine · The Ohio State University
- Demond Handley
Medicine · The Ohio State University
- JC Chen
Medicine · The Ohio State University
- James L. Fisher
Medicine · The Ohio State University
- Amy C. Ogilvie
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile